Trials / Completed
CompletedNCT04549701
Inferior Vena CAVA and Lung UltraSound-guided Therapy in Acute Heart Failure
Inferior Vena CAVA and Lung UltraSound-guided Therapy in Acute Heart Failure: a Randomized Controlled Pilot Trial (CAVAL US-AHF Study)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Instituto Cardiovascular de Buenos Aires · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Between 25% and 30% of patients hospitalized for acute heart failure (AHF) are readmitted within 90 days after discharge. Mostly due to persistent congestion on discharge. However, as the optimal evaluation of decongestion is not clearly defined, it is necessary to implement new tools to identify subclinical congestion to guide treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | CAVAL US-guided Therapy | Patients randomly assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to treating medical team, in addition to the standard care. |
| OTHER | Standard of care | Standard of care will be provided. |
Timeline
- Start date
- 2022-03-20
- Primary completion
- 2023-01-31
- Completion
- 2023-02-28
- First posted
- 2020-09-16
- Last updated
- 2024-06-04
Locations
2 sites across 1 country: Argentina
Source: ClinicalTrials.gov record NCT04549701. Inclusion in this directory is not an endorsement.